Sabby Management’s Amicus Therapeutics FOLD Stock Holding History

Sabby Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-155,044	Closed	-$1.87M	–	131
2018 Q3	$1.87M	Buy	155,044 +116,700	+304%	+$1.63M	0.24%	42
2018 Q2	$599K	Sell	38,344 -26,566	-41%	-$402K	0.09%	78
2018 Q1	$976K	Buy	+64,910	New	+$988K	0.12%	64
2017 Q1	–	Sell	-60,309	Closed	-$381K	–	277
2016 Q4	$300K	Buy	+60,309	New	+$417K	0.02%	228
2016 Q3	–	Sell	-125,912	Closed	-$850K	–	317
2016 Q2	$687K	Buy	125,912 +66,588	+112%	+$466K	0.04%	196
2016 Q1	$501K	Buy	59,324 +33,663	+131%	+$238K	0.03%	212
2015 Q4	$249K	Buy	+25,661	New	+$231K	0.01%	274
2015 Q1	–	Sell	-246,697	Closed	-$2.17M	–	306
2014 Q4	$2.05K	Buy	+246,697	New	+$1.69M	0.06%	122
2014 Q3	–	Sell	-100,000	Closed	-$334K	–	272
2014 Q2	$334K	Buy	+100,000	New	+$235K	0.01%	206

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sabby Management's FOLD Position: Q4 2018 in Review

Sabby Management sold out of Amicus Therapeutics (FOLD) in Q4 2018, closing a stake of 155,044 shares — an estimated $1.87M sold.

Sabby Management first reported a position in FOLD in Q2 2014 and held it in 9 quarters. The position peaked at $1.87M in Q3 2018. 195 funds tracked by Wall St. Rank hold FOLD as of Q4 2018.

Sabby Management reported no remaining Amicus Therapeutics position as of Q4 2018 after selling out during the quarter.
Sabby Management sold 155,044 Amicus Therapeutics shares in Q4 2018, an estimated $1.87M.
Sabby Management first reported a position in Amicus Therapeutics in Q2 2014 and held it in 9 quarters.
Sabby Management's Amicus Therapeutics position peaked at $1.87M in Q3 2018.
195 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2018.

Based on Sabby Management's 13F filing for Q4 2018, filed 14 Feb 2019.